NICE recommends Alnylam’s treatment for hereditary amyloidosis
Pf Media,
The National Institute for Health and Care Excellence (NICE) has published a draft decision recommending the use of AMVUTTRA ® (v…
The National Institute for Health and Care Excellence (NICE) has published a draft decision recommending the use of AMVUTTRA ® (v…
Published date: 19/01/2023 MAIDENHEAD, UK, 19th January 2023 – Alnylam UK Limited, the leading RNA interference (RNAi…